Crinetics Highlights Strong PALSONIFY Launch and Trial Progress

The latest announcement is out from Crinetics Pharmaceuticals ( (CRNX) ).

On January 5, 2026, Crinetics Pharmaceuticals reported strong early U.S. launch metrics for PALSONIFY, its recently FDA-approved first-line acromegaly treatment, including unaudited preliminary net product revenue of more than $5 million in the fourth quarter of 2025, over 200 patient enrollment forms, more than 125 unique prescribers split evenly between community and pituitary centers, and favorable reimbursement dynamics with many prescriptions filled without bridge supplies and prior authorizations typically lasting 12 months. At the same time, the company released positive topline data from the fourth cohort and open-label extension of its Phase 2 TouCAHn trial of atumelnant in adults with classic congenital adrenal hyperplasia, showing a 67% mean reduction in androstenedione levels and successful glucocorticoid dose reduction to physiologic levels in most completers, alongside a favorable safety profile with no serious or treatment-related severe adverse events and no hepatic transaminase issues, reinforcing the candidate’s potential to strengthen Crinetics’ endocrine portfolio and future market positioning in CAH and ACTH-driven disorders.

The most recent analyst rating on (CRNX) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.

Spark’s Take on CRNX Stock

According to Spark, TipRanks’ AI Analyst, CRNX is a Neutral.

Crinetics Pharmaceuticals’ overall stock score is driven by the successful launch of PALSONIFY and positive technical indicators, suggesting potential growth. However, financial challenges and valuation concerns due to ongoing losses and a negative P/E ratio temper the outlook. The strong financial position and FDA approval provide a solid foundation for future performance.

To see Spark’s full report on CRNX stock, click here.

More about Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a global pharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for endocrine diseases and endocrine-related tumors, with core expertise in targeting G-protein coupled receptors (GPCRs) to address conditions such as acromegaly, congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome.

Average Trading Volume: 1,300,337

Technical Sentiment Signal: Buy

Current Market Cap: $4.43B

Find detailed analytics on CRNX stock on TipRanks’ Stock Analysis page.